Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.
- DOI
- 10.1016/j.clml.2023.12.005
- Published
- 2023-12-12
- Container
- Clin Lymphoma Myeloma Leuk
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.clml.2023.12.005,
title = {Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.},
author = {Matasar M and Bartlett NL and Shadman M and Budde LE and Flinn I and Gregory GP and Kim WS and Hess G and El-Sharkawi D and Diefenbach CS and Huang H and To I and Parreira J and Wu M and Kwan A and Assouline S.},
year = {2024},
journal = {Clin Lymphoma Myeloma Leuk},
doi = {10.1016/j.clml.2023.12.005},
url = {https://doi.org/10.1016/j.clml.2023.12.005}
}RIS
TY - JOUR TI - Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial. AU - Matasar M AU - Bartlett NL AU - Shadman M AU - Budde LE AU - Flinn I AU - Gregory GP AU - Kim WS AU - Hess G AU - El-Sharkawi D AU - Diefenbach CS AU - Huang H AU - To I AU - Parreira J AU - Wu M AU - Kwan A AU - Assouline S. PY - 2024 JO - Clin Lymphoma Myeloma Leuk DO - 10.1016/j.clml.2023.12.005 UR - https://doi.org/10.1016/j.clml.2023.12.005 ER -
APA
M, M., NL, B., M, S., LE, B., I, F., GP, G., WS, K., G, H., D, E., CS, D., H, H., I, T., J, P., M, W., A, K., & S., A. (2024). Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.. Clin Lymphoma Myeloma Leuk. https://doi.org/10.1016/j.clml.2023.12.005
Source records
- europe-pmc · retrieved 2026-09-26T10:01:55.039Z